KirinKunpeng

KirinKunpeng is a biopharmaceutical joint venture between Kyowa Kirin and Kunpeng Biopharmaceutical, based in Shenzhen, China. The company focuses on the development, manufacturing, and commercialization of high-quality biologics, including biosimilars and innovative therapeutic antibodies, for the Chinese market. By combining Kyowa Kirin's global R&D expertise with Kunpeng's local manufacturing and regulatory capabilities, KirinKunpeng aims to provide affordable therapeutic options in hematology, oncology, and nephrology. Its pipeline includes late-stage biosimilar programs for treatments such as Romiplostim and Pegfilgrastim. The venture represents a strategic effort to accelerate the entry of advanced biologic therapies into the rapidly growing Chinese healthcare sector.